Discussion: Here I suggest that variant V12 emerged upon D614G deletion in V1, variant V13 upon E96D substitution in V1, variant V15 upon P809S substitution in V1 and variant V19 upon L5F substitution in N-terminal domain of V1.
Association between prognostic factors and the outcomes of patients infected with SARS-CoV-2 harboring multiple spike protein mutations.
Discussion: One strain had two S gene mutations, D614G and L5F.
Molecular characterization of SARS-CoV-2 from Bangladesh: implications in genetic diversity, possible origin of the virus, and functional significance of the mutations.
Figure: Mutated amino acid positions shown in the human ACE2 receptor bound structure (PDB ID: 6acj) of SARS-CoV-2 spike protein (except L5F, S13I, Q14H, G75V, T76I, Y145del, H146Y, Q675 H/R, Q677H, N679K, I834V, R1185H and K1195N as the regions were not covered in the structure).
Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.
Abstract: In the mutational analysis, we found 639 mutations in the spike protein sequence of SARS-CoV-2 and identified/highlighted 20 common mutations L5F, T22I, T29I, H49Y, L54F, V90F, S98F, S221L, S254F, V367F, A520S, T572I, D614G, H655Y, P809S, A879S, D936Y, A1020S, A1078S, and
Emerging mutation in SARS-CoV-2 spike: Widening distribution over time in different geographic areas.
Discussion: For example, many of the favorably selected variants, such as L18F, L5F (spike); R203K, G204R, and A220V (nucleocapsid), were found to be destabilizing the respective protein structure (Table 1).
Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.
Introduction: B.1.526-E484K and B.1.526-S477N share the characteristic spike protein mutations L5F, T95I, D253G, D614G and either A701V or Q957R, along with either E484K or S477N.
Introduction: Pseudoviruses were constructed containing S477N or E484K alone, or containing all five signature mutations (L5F, T95I, D253G, A701V and E484K or S
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Introduction: The B.1.526 variant spike proteins contain the D614G mutation, a shared set of novel mutations (L5F, T95I, D253G, and A701V), and either E484K or S477N, both of which lie within the RBD.
Introduction: Two versions of B.1.526 were identified, both having the D614G and A701V mutations and, in addition, the mutations L5F, T95I, and D253G, which are not present in previously reported variants.
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York.
Abstract: The most common sets of spike mutations in this lineage (now designated as B.1.526) are L5F, T95I, D253G, E484K or S477N, D614G, and A701V.
Method: Human plasma samples were assayed for neutralization activity against lentiviruses pseudotyped with SARS-CoV-2 spike containing a 21-amino acid cytoplasmic tail deletion and either D614G or mutations corresponding to lineage B.1.526 (v.1: L5F, T95I, D253G, E484K, D614G, and A701V; v.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Meta gene
Browser Board
Co-occurred Entities
Filtrator
ViMRT